Doripenem-d4 (sodium salt)
目录号 : GC47265
A neuropeptide with diverse biological activities
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Doripenem-d4 is intended for use as an internal standard for the quantification of doripenem by GC- or LC-MS. Doripenem is a broad-spectrum antibiotic in the β-lactam subclass known as carbapenems.1,2 It is active against Gram-negative and Gram-positive bacteria, including S. aureus, S. pneumoniae, E. coli, and K. pneumoniae (MICs = 0.03-0.06, 0.016-0.06, <0.015-0.3, and 0.03-0.06 µg/ml, respectively).1,2,3,4 Doripenem reduces the number of viable bacteria in mouse lung in a model of chronic P. aeruginosa respiratory tract infection when administered at a dose of 100 mg/kg per day.5 It inhibits bacterial cell wall synthesis by forming stable acyl enzymes with penicillin-binding proteins, thereby inactivating them.2 Formulations containing doripenem have been used in the treatment of bacterial infections.
1.Mandell, L.Doripenem: A new carbapenem in the treatment of nosocomial infectionClin. Infect. Dis.49(Suppl 1)S1-S3(2009) 2.Paterson, D.L., and DePestel, D.D.DoripenemClin. Infect. Dis.49(2)291-298(2009) 3.Papp-Wallace, K.M., Endimiani, A., Taracila, M.A., et al.Carbapenems: Past, present, and futureAntimicrob. Agents Chemother.55(11)4943-4960(2011) 4.El Solh, A.A., and Alhajhusain, A.Update on the treatment of Pseudomonas aeruginosa pneumoniaJ. Antimicrob. Chemother.64(2)229-238(2009) 5.Araki, N., Yanagihara, K., Morinaga, Y., et al.In vivo efficacy of doripenem (DRPM) against Pseudomonas aeruginosa in murine chronic respiratory tract infection modelJ. Infect. Chemother.17(3)318-321(2011)
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.2396 mL | 11.1982 mL | 22.3964 mL |
| 5 mM | 0.4479 mL | 2.2396 mL | 4.4793 mL |
| 10 mM | 0.224 mL | 1.1198 mL | 2.2396 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。